Lexaria Biosci News - LARVOL Sigma

||||||||||  cannabidiol (DehydraTECH-CBD) / Lexaria Biosci, DehydraTECH-semaglutide / Lexaria Biosci
Enrollment closed, Enrollment change:  Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants (clinicaltrials.gov) -  Jul 11, 2025
P1, N=148, Active, not recruiting,  Sponsor: Lexaria Bioscience Corp.
Recruiting --> Active, not recruiting | N=80 --> 148

||||||||||  cannabidiol (DehydraTECH-CBD) / Lexaria Biosci, DehydraTECH-semaglutide / Lexaria Biosci
Enrollment open:  Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants (clinicaltrials.gov) -  Mar 9, 2025
P1, N=80, Recruiting,  Sponsor: Lexaria Bioscience Corp.
Recruiting --> Active, not recruiting | N=80 --> 148 Not yet recruiting --> Recruiting

||||||||||  cannabidiol (DehydraTECH-CBD) / Lexaria Biosci, DehydraTECH-semaglutide / Lexaria Biosci
New P1 trial:  Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants (clinicaltrials.gov) -  Oct 17, 2024
P1, N=80, Not yet recruiting,  Sponsor: Lexaria Bioscience Corp.

|||||||||| cannabidiol (DehydraTECH-CBD) / Lexaria Biosci
Journal: Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study. (Pubmed Central) - Jul 2, 2023
Here, we report a triple-blind (participant, investigator, and outcome assessor) placebo-controlled crossover study in which 62 hypertensive volunteers were randomly assigned to receive the recently developed DehydraTECH2.0 CBD formulation or a placebo...Significantly higher plasma CBD concentrations occurred in females compared to males, which was potentially related to greater adipose tissue. More research is needed to optimize CBD doses to consider the differential therapeutic benefits in men and women.

|||||||||| cannabidiol (DehydraTECH-CBD) / Lexaria Biosci
Biomarker, Journal: Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study. (Pubmed Central) - May 27, 2023
Both CYP2C19*2 (p = 0.037) and CYP2C19*17 (p = 0.022) were negatively associated with urinary CBD levels (beta = -0.489 for CYP2C19*2 and beta = -0.494 for CYP2C19*17). Further research is required to establish the impact of CYP P450 enzymes and the identification of metabolizer phenotype for the optimization of CBD formulations.

|||||||||| cannabidiol (DehydraTECH-CBD) / Lexaria Biosci
Journal: Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study. (Pubmed Central) - Jul 29, 2022
The present single-center study is designed as a triple blind (Participant, Investigator, Outcomes Assessor), placebo-controlled, crossover pilot study in which 70 hypertensive volunteers (aged 40-70 years) will receive DehydraTECH2.0 CBD formulation and placebo in a crossover manner. We believe that comprehensive analyses that will be performed in the present trial will decipher whether CBD is in fact a safe and valuable supplement for patients with treated and untreated hypertension.



	Diseases Companies Products Productz Mechanisms of Action Sites